Statin + fibrate combination therapy. Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

International Journal of Cardiology

Volumn 69, Issue 3, 1999, Pages 237-244

  Papadakis, John A ^a   Ganotakis, Emanuel S ^a   Jagroop, Indera A ^a   Winder, Anthony F ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bezafibrate; Ciprofibrate; Fibrinogen; Fluvastatin; Hyperlipidaemia; Vascular disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; BILIRUBIN; CHOLESTEROL; CIPROFIBRATE; CREATINE KINASE; FIBRINOGEN; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERLIPIDEMIAS; INDOLES; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0033153214     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(99)00013-3     Document Type: Article

References (52)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl J Med. 335:1996;1001-1009.
3. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med. 333:1995;1301-1307.
4. Downs J.R., Clearfield M., Weis S.et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc. 279:1998;1615-1622.
5. Jeppensen J., Hein H.O., Suadicani P., Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 17:1997;1114-1120.
6. Tanne D., Yaari S., Goldbourt U. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischaemic Heart Disease Study. Stroke. 28:1997;83-87.
7. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 70:1992;733-737.
8. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridaemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
9. Lindenstrom E., Boysen G., Nyboe J. Influence of total cholesterol, high-density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br Med J. 309:1994;11-15.
10. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:1996;213-219.
11. Bezafibrate Infarction Prevention Study. Presented at XXth Congress of the European Society of Cardiology, Vienna, August 1998.
12. East C., Bilheimer D.W., Grundy S.M. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 109:1988;25-32.
13. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc. 264:1990;71-75.
14. Leitersdorf E., Muratti E.N., Eliav O.et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med. 96:1994;401-407.
15. Feher M.D., Foxton J., Banks D., Lant A.F., Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J. 74:1995;14-17.
16. Horsmans Y., Desager J.P., Harvengt C. Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol. 32:1992;422-426.
17. Southworth M.R., Mauro V.F. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother. 31:1997;489-491.
18. Glueck C.J., Oakes N., Speirs J., Tracy T., Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol. 70:1992;1-9.
19. Duell P.B., Connor W.E., Illingworth D.R. Rabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 81:1998;368-369.
20. van Puijenbroek E.P., Du Buf-Vereijken P.W., Spooren P.F., van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 240:1996;403-404.
21. Wierzbicki A.S., Lumb P.J., Cheung J., Crook M.A. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. Q J Med. 90:1997;631-634.
22. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Didangelos T.P., Carina M.V., Kranitsas D.F., Kontopoulos A.G. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 80:1997;608-613.
23. Kehely A., MacMahon M., Barbir M., Wray R., Hunt B.J., Prescott R.J., Thompson G.R. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. Q J Med. 88:1995;421-427.
24. Eliav O., Schurr D., Pfister P., Friedlander Y., Leitersdorf E. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol. 76:1995;76A-79A.
25. Muratti E.N., Peters T.K., Leitersdorf E. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. Am J Cardiol. 73:1994;30D-38D.
26. Montgomery H.E., Clarkson P., Nwose O.M.et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscl Throm Vasc Biol. 16:1996;386-391.
27. Dahlen G.H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 108:1994;111-126.
28. Betteridge D.J., O'Bryan-Tear C.G. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Postgrad Med J. 72:1996;739-743.
29. Fruchart J.C., Brewer H.B. Jr., Leitersdorf E.B. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 81:1998;912-917.
30. Bruckert E., Dejager S., Chapman M.J. Ciprofibrate therapy normalises the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 100:1993;91-102.
31. Gaw A., Packard C.J., Caslake M.et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 108:1994;137-148.
32. Ganotakis E.S., Mikhailidis D.P. Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. Today Therap Trends. 13:1996;231-249.
33. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominace of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
34. Kontopoulos A.G., Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Mayroudi M.C., Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coronary Artery Dis. 7:1996;843-850.
35. Heinrich J., Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk. 2:1995;197-205.
36. Levenson J., Giral P., Razavian M., Gariepy J., Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscl Thromb Vasc Biol. 15:1995;1263-1268.
37. Levenson J., Giral P., Megnien J.L., Gariepy J., Plainfosse M.C., Simon A. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscl Throm Vasc Biol. 17:1997;45-50.
38. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol 1998; in press.
39. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
40. Maggi F.M., Piglionica M.R., De Michaele L., Baroni S., Biasi G.M., Catapano A.L. Bezafibrate lowers elevated plasma levels of fibrinogen and lipoprotein (a) in patients with type IIa and b dyslipoproteinaemia. Nutr Metab Cardiovasc Dis. 4:1994;215-220.
41. Nair D.R., Papadakis J.A., Jagroop I.A., Mikhailidis D.P., Winder A.F. Statins and fibrinogen. Lancet. 351:1998;1430.
42. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvastatin on plasma fibrinogen. Lancet. 351:1998;569-570.
43. Inoue I., Takahashi K., Katayama S.et al. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabet Res Clin Pract. 25:1994;199-205.
44. Zambrana J.L., Velasco F., Castro P.et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol. 80:1997;836-840.
45. Mathur S., Barradas M.A., Mikhailidis D.P.et al. The effects of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diabetes Res. 14:1990;133-138.
46. Shinozaki K., Suzuki M., Ikebuchi M., Hara Y., Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care. 19:1996;1-7.
47. Seibaek M., Sloth C., Vallebo L.et al. Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. Am Heart J. 133:1997;622-629.
48. Pais P., Pogue J., Gerstein H.et al. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet. 348:1996;358-363.
49. Day A.P., Feher M.D., Chopra R., Mayne P.D. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 42:1993;839-842.
50. Ganotakis E.S., Jagroop I.A., Hamilton G., Winder A.F., Mikhailidis D.P. Preliminary report: ciprofibrate-fluvastatin combination therapy for dyslipidaemia. J Drug Dev Clin Pract. 8:1996;171-175.
51. Riegger G, Abletshauser C, Ludwing M, Schwandt P, Wetzel D, Weidinger G. New studies in the assessment of the role of statins in CHD: The LiSA Study. XIIth International Symposium on Drugs Affecting Lipid Metabolism, Florence, May 1998; Abstract: 71.
52. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol. 81:1998;582-587.